Nilotinib

Nilotinib is an antineoplastic agent and shows its activity through tyrosine kinase inhibitor that is used for the treatment of chronic myeloid leukaemia.chemically it is Nilotinibum. 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]- amino}benzamide

Brands
Adult Dose
Neonatal
Paedriatic
Characteristics
Nilotinib also known as AMN 107, AMN 107. . It is of Synthetic origin and belongs to n-phenylbenzamides. It belongs to Tyrosine kinase inhibitor pharmacological group on the basis of mechanism of action. The Molecular Weight of Nilotinib is 529.51.
Contraindications
Nilotinib
Effects
The severe or irreversible adverse effects of Nilotinib, which give rise to further complications include Thrombocytopenia, Neutropenia, Pneumonia, Leukopenia, febrile neutropenia, intracranial hemorrhage, pyrexia, febrile neutropenia, intracranial hemorrhage, eleated lipase.The symptomatic adverse reactions produced by Nilotinib are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fatigue, Nausea, Vomiting, Diarrhea, Pruritis, Rash.
Indications
Nilotinib is primarily indicated in conditions like Myeloid leukaemia.
Interactions
No data regarding the interactions of Nilotinib was found.
Interfrence
elevated blood glucoseelevated lipids
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
capsule Store Between 15°C-30°C. Do not Freeze. Protect from Sunlight and Heat.
Warnings
Myelosuppression: Associated with neutropenia, thrombocytopenia and anemia. CBC should be done every 2 weeks for the first 2 months, then monthly. Reversible by withholding dose. Dose reduction may be required. nilotinib prolongs the QT interval. Correct hypokalemia or hypomagnesemia prior to administration and monitor periodically.Caution is recommended in patients with history of pancreatitis. Check serum lipase periodically. nilotinib may result in elevations in bilirubin, AST/ALT, and alkaline phosphatase. Check hepatic function tests periodically. nilotinib can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Correct electrolyte abnormalities prior to initiating Tasigna and monitor periodically during therapy. Food increases blood levels of nilotinib . Avoid food 2 hours before and 1 hour after a dose.Fetal harm can occur when administered to a pregnant woman.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.